by Raynovich Rod | Oct 4, 2021 | 2024-25 Life Science Portfolios, Biopharmaceuticals, vaccines
Update-2 10/7/21…Nice broad rally day with temporary relief from the political spat on the debt ceiling. All of our mid-cap focus stocks were up: CRSP CYRX PACB QDEL and VCYT. We need to get confirmation of bottom on small/mid caps in life science stocks with...
by Raynovich Rod | Sep 27, 2021 | 2024-25 Life Science Portfolios
Update-3 10/1 10:35a …Merck Oral COVID Drug disrupts markets.MRK up 9% vaccine stocks down. IBB down 3.2% to $156 handle. Update-3 (continued at 10/1 close) Merck oral COVID drug leads rally with all major Indices up, Dow Up 1.43%, S&P 500 up 1.15%, NAZ up...
by Raynovich Rod | Sep 20, 2021 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
Update 3…IBB teetering along SEP Support of $170: 9/24..A lot of red today XBI down 2%. Large caps down as well. BNTX down over 5%. Update-2 Another good day for life science stocks. Still expecting a Q4 biotech bounce in small/mid-cap stocks. FED Meeting...
by Raynovich Rod | Sep 16, 2021 | 2024-25 Life Science Portfolios, Biopharmaceuticals
Biotech Bounce in Mid-Small Caps- life science stocks find buyers. Bellwether tickers : ARKG up 3% to $83.93, XBI up 1.44% to $132.88. Update-1 …Triple witching selling pressure again as expected but a little green at the end of day. DJI down 0.48%, NASDAQ down...
by Raynovich Rod | Sep 9, 2021 | 2024-25 Life Science Portfolios, Biopharmaceuticals
Update-1 Five days of selling but looks like routine re-balancing at market highs. NASDAQ leads way down 0.7% Whether it is concerns about Washington or a seasonal buyers strike or even an extended summer vacation who knows? The 3.3% drop in AAPL on App Store ruling...
by Raynovich Rod | Aug 30, 2021 | 2024-25 Life Science Portfolios
Update-1 3:45P 9/1 FDA issues warning on JAK Inhibitor drug class. ABBV down 7%., PFE and LLY drugs also affected. Small cap rally intact: CRSP,CYRX, VCYT. Quidel (QDEL) up 5.45% on need for more COVID tests. ARKG and XBI up about 1.5%. Mid-caps all green. IBB up...
by Raynovich Rod | Jul 12, 2021 | 2024-25 Life Science Portfolios, Healthcare stocks
Update-3 JY 20…a good reversal day! Our healthcare portfolio strategy is working well even on volatile days.All major averages were up about 1.5% today and most biotechs did better.The XLV was up 1.2% to $128.82.We will post a new article at the end of the...
by Raynovich Rod | Jul 2, 2021 | 2024-25 Life Science Portfolios
Update-1 8:45am Vacation through Friday:Asia down, Futures down over 1% on growth concerns. Technicals look toppy on ARKG and XBI. New Mid-Cap Biotech Picks Momentum indicators for tracking and trading:ARKG and XBI. All three recent mid-cap biotech picks are up since...
by Raynovich Rod | Jun 18, 2021 | 2024-25 Life Science Portfolios, Biopharmaceuticals
Update-1 6/18 On a Risk-Off Day with Selling at Close NASDAQ down 0.92% to 14030, ARKG down 0.62%,IBB down 0.185, XBI down 0.6%, XLV down 1.14% at $123.74. iShares Medical Device ETF (IHI) down 0.65% at $350.67. Focus Mid-Cap Life Science Stocks: CYRX down 1.77% to...
